TBPH · Transaction Mar 24, 2025 · Filed Apr 23, 2025 · $15,001 to $50,000
XNAS · TBPH
-0.06% · -$0.0100 · Vol 6.2M
After hours · updated 16:45:56 ET
Theravance Biopharma, Inc.
PHARMACEUTICAL PREPARATIONS
$17.04
Follow $TBPH
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TBPH by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredTue Sep 22 · session closed · Markets closed · resumes Wed 9:30 ET · TBPH
MethodologyEarnings absence reason unknown · Analyst data unavailable at compute time
TBPH
Theravance Biopharma, Inc.
Tue Sep 22 · session closed · Markets closed · resumes Wed 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
50/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Tue Sep 22 · session closed · Markets closed · resumes Wed 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is TBPH moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Theravance Biopharma, Inc.
PHARMACEUTICAL PREPARATIONSListed since
2014
Employees
90
Country
US
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$17.04
Day high
$17.08
Day low
$17.03
Previous close
$17.05
52W high
$20.74
-17.84% from high
52W low
$13.57
48% of range
Market cap
$885.2M
EPS
$-0.4100
Beta
-0.13
Shares out
51.9M
Volume
6.2M
10.10× rel vol
Avg volume
609.9K
VWAP
$17.04
Price history computed in-house
1W
0.00%
1M
+0.18%
3M
-1.33%
1Y
+21.11%
YTD
-8.93%
SMA 50 $16.96 · above
SMA 200 $17.19 · below
52W position 48%
TBPH overview
Related filings and maps
Public disclosures
Congress activity in TBPH
Official filing ↗
Theravance Biopharma, Inc. - Ordinary Shares · Transaction Mar 24, 2025 · Filed Apr 23, 2025 · $15,001 to $50,000
Federal contracts
TBPH contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TBPH in this window.
Lobbying spend
TBPH lobbying filings, year to date.
Registered lobbying filings matched to Theravance Biopharma, Inc..
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TBPH in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for TBPH.
Options
Sovereign unlock shows live options positioning for TBPH.